GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:001050632 | Thyroid | ATC | regulation of autophagy | 180/6293 | 317/18723 | 1.34e-17 | 1.46e-15 | 180 |
GO:001056334 | Thyroid | ATC | negative regulation of phosphorus metabolic process | 234/6293 | 442/18723 | 2.30e-17 | 2.31e-15 | 234 |
GO:006219734 | Thyroid | ATC | cellular response to chemical stress | 188/6293 | 337/18723 | 3.16e-17 | 3.07e-15 | 188 |
GO:004593634 | Thyroid | ATC | negative regulation of phosphate metabolic process | 233/6293 | 441/18723 | 3.68e-17 | 3.47e-15 | 233 |
GO:000193333 | Thyroid | ATC | negative regulation of protein phosphorylation | 186/6293 | 342/18723 | 1.43e-15 | 1.08e-13 | 186 |
GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
GO:003459934 | Thyroid | ATC | cellular response to oxidative stress | 158/6293 | 288/18723 | 7.35e-14 | 3.94e-12 | 158 |
GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
GO:2001234210 | Thyroid | ATC | negative regulation of apoptotic signaling pathway | 129/6293 | 224/18723 | 1.26e-13 | 6.46e-12 | 129 |
GO:000030234 | Thyroid | ATC | response to reactive oxygen species | 128/6293 | 222/18723 | 1.38e-13 | 7.00e-12 | 128 |
GO:004254233 | Thyroid | ATC | response to hydrogen peroxide | 92/6293 | 146/18723 | 3.12e-13 | 1.46e-11 | 92 |
GO:0097191210 | Thyroid | ATC | extrinsic apoptotic signaling pathway | 125/6293 | 219/18723 | 7.19e-13 | 3.16e-11 | 125 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:001063926 | Thyroid | ATC | negative regulation of organelle organization | 179/6293 | 348/18723 | 3.74e-12 | 1.50e-10 | 179 |
GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
GO:2001236210 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway | 89/6293 | 151/18723 | 1.43e-10 | 4.40e-09 | 89 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HGF | SNV | Missense_Mutation | novel | c.278G>T | p.Arg93Ile | p.R93I | P14210 | protein_coding | tolerated(0.21) | benign(0) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | novel | c.73G>A | p.Ala25Thr | p.A25T | P14210 | protein_coding | tolerated(0.7) | benign(0) | TCGA-EY-A2OO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
HGF | SNV | Missense_Mutation | rs865828369 | c.751C>T | p.Pro251Ser | p.P251S | P14210 | protein_coding | tolerated(0.05) | possibly_damaging(0.711) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | rs766769838 | c.1715A>G | p.Tyr572Cys | p.Y572C | P14210 | protein_coding | tolerated(1) | probably_damaging(0.927) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
HGF | SNV | Missense_Mutation | rs758567520 | c.1177C>T | p.Arg393Cys | p.R393C | P14210 | protein_coding | deleterious(0.04) | possibly_damaging(0.718) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
HGF | insertion | Frame_Shift_Ins | novel | c.330_331insA | p.Glu111ArgfsTer5 | p.E111Rfs*5 | P14210 | protein_coding | | | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HGF | insertion | Frame_Shift_Ins | novel | c.189_190insA | p.Val64SerfsTer9 | p.V64Sfs*9 | P14210 | protein_coding | | | TCGA-AP-A0LE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | novel | c.1448C>A | p.Pro483His | p.P483H | P14210 | protein_coding | deleterious(0.03) | possibly_damaging(0.781) | TCGA-BC-A217-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | novel | c.1092N>C | p.Trp364Cys | p.W364C | P14210 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DD-AACZ-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
HGF | SNV | Missense_Mutation | | c.790G>T | p.Asp264Tyr | p.D264Y | P14210 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-G3-A5SL-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | STI571 | IMATINIB MESYLATE | 11439348 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | THALIDOMIDE | THALIDOMIDE | 15939924 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | ASPIRIN | ASPIRIN | 11981761 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | VM-202 | | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | Ficlatuzumab | FICLATUZUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | PROTEOLYTIC ENZYMES | | 9502079 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | antibody | RILOTUMUMAB | RILOTUMUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | RESVERATROL | RESVERATROL | 15672869 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | TAK-701 | | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | FICLATUZUMAB | FICLATUZUMAB | |